.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,175,145

« Back to Dashboard

Claims for Patent: 5,175,145

Title: Treatment of diabetes mellitus with amylin agonists
Abstract:Novel methods for treating diabetes mellitus and hyperglycemia are described which comprise administering to a diabetic or hypoglycemic subject an amount of an amylin agonist effective to induce amylin activity in said subject. Various amylin agonist compounds, and therapeutic methods utilizing such compounds, are also disclosed.
Inventor(s): Cooper; Garth J. S. (Woodstock, GB2)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:07/821,479
Patent Claims: 1. A method of treating diabetes mellitus in a subject comprising administering to said subject an amount of an amylin agonist effective to induce amylin activity in said subject.

2. The method of claim 1 wherein said amylin agonist is amylin.

3. The method of claim 1 wherein said amylin agonist is CGRP.

4. The method of claim 1 wherein said amylin agonist is a conservative variant of amylin.

5. The method of claim 1 wherein said amylin agonist is a conservative variant of CGRP.

6. The method of claim 2 wherein said amylin is human amylin.

7. The method of claim 3 wherein said CGRP is human CGRP.

8. A method of treating hypoglycemia in a subject comprising administering to said subject an amount of an amylin agonist effective to induce amylin activity in said subject.

9. The method of claim 8 wherein said amylin agonist is amylin.

10. The method of claim 8 wherein said amylin agonist is CGRP.

11. The method of claim 8 wherein said amylin agonist is a conservative variant of amylin.

12. The method of claim 8 wherein said amylin agonist is a conservative variant of CGRP.

13. The method of claim 9 wherein said amylin is human amylin.

14. The method of claim 10 wherein said CGRP is human CGRP.

15. The method of claim 1 or 8 further comprising administering a predetermined amount of an insulin to said subject.

16. A method of treating diabetes mellitus comprising administering a pharmaceutical composition comprising an amylin agonist and an insulin.

17. The method of claim 16 wherein the molar ratio of said insulin to said amylin agonist is from 100:1 to 0.1:1.

18. The method of claim 16 wherein said amylin agonist is amylin.

19. The method of claim 18 wherein said amylin is human amylin.

20. The method of claim 1 or 8 wherein said amylin agonist is administered parenterally.

21. The method of claim 15 wherein said insulin is administered parenterally.

22. The method of claim 16 wherein said composition is administered parenterally.

23. The method of claim 1 or 8 wherein amylin agonist is administered in a vehicle suitable for delayed release administration.

24. The method of claim 15 wherein said insulin is administered in a vehicle suitable for delayed release administration.

25. The method of claim 16 wherein said composition is administered in a vehicle suitable for delayed release administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc